Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib

Pharmaceutical Investing

Onconova Therapeutics (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced that the United States Patent and Trademark Office issued a new patent protecting the company’s lead product candidate, Rigosertib. As quoted in the press release: U.S. patent …

Onconova Therapeutics (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced that the United States Patent and Trademark Office issued a new patent protecting the company’s lead product candidate, Rigosertib.

As quoted in the press release:

U.S. patent 10,098,862 “Formulations with enhanced stability and bioavailability for administration of (E)-2, 6-Dialkoxystyryl 4-Substituted Benzyl Sulfones” describes novel compositions directed towards improving stability and enhancing bioavailability of Rigosertib.  The issued patent claims novel formulations for oral and parenteral administration and oral dosing regimens of Rigosertib for the treatment of cancer and proliferative disorders.

“Rigosertib is well protected by issued US and foreign patents as well as by Orphan Designation in the U.S., Europe, and Japan. We remain focused on our broader IP strategy that provides additional barriers to entry and expanded geographical coverage for our lead product candidate, which is in advanced clinical trials for unmet medical needs of patients with Myelodysplastic Syndromes,” commented, Ramesh Kumar, Chief Executive Officer of Onconova. “Ensuring multi-faceted intellectual property protection around Rigosertib helps enhance the potential value of this innovative program.”

Click here to read the full press release.

The Conversation (0)
×